Attached files

file filename
EX-3.I - ENTEST BIOMEDICAL, INC.entest_ex3i.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): June 9, 2011
 
 
ENTEST BIOMEDICAL, INC.
(Exact Name of Company as Specified in Charter)
 
Nevada
333-154989
26-3431263
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification Number)

4700 Spring Street, St 203
La Mesa California, 91942
(Address of Principal Executive Offices, Zip Code)

619 702 1404
(Company’s telephone number, including area code)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
[   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 











 
 

 

Item 3.03 Material Modification to Rights of Security Holders.
 
On June 6, 2011 Entest BioMedical, Inc. (“Company”) filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada  Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”).
 
The Board of Directors of the Company have authorized 100,000 shares of the Series AA Preferred Stock, par value $0.001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,0000). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders.
 
The issuance of the AA Stock, with disproportionately high voting rights, will adversely affect the voting power of holders of common stock of the Company.
 
Item 9.01 Financial Statements and Exhibits.
 
 
Exhibit No.
 
Description of Exhibit
     
3(i)
 
Certificate of Designations


 
 
 
 
 

 



 
2

 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
ENTEST BIOMEDICAL, INC.
 
 
By: /s/ David R. Koos
David R. Koos
Chief Executive Officer
Dated: June 9, 2011
 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 




 
3